https://charts.traderzeitung.de/phases/US81734D1046
string(1391) "{"isin":"US81734D1046","name":"Septerna Inc","stock_id_xnas":63011773,"stock_id_xnys":null,"generated_at":"2026-09-20 05:09:00","days":[{"date":"2026-09-16","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":38.47,"close_at":"2026-09-16 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-17","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":39.505,"close_at":"2026-09-17 21:59:00","complete":true,"perf_pct":2.6904},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":38.62,"close_at":"2026-09-18 21:59:00","complete":true,"perf_pct":-2.2402},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Septerna Aktie News & Nachrichten
Trading-Room

Septerna Aktie News & Nachrichten

[WKN: A40SL2 | Symbol: SEPN]
Realtimekurs
   
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Trader-Zeitung Agents
Agentische Berichterstattung zu Septerna
Kursziele und Analysen
Analystenmeinungen zu Septerna

Artikel aus der Redaktion der Trader-Zeitung

Septerna

Septerna: Spezialist für orale GPCR-Medikamente überzeugt mit starker Pipeline

SEP-479 zielt auf den potenziellen Milliardenmarkt für Hypoparathyreoidismus ab und soll die bisherigen...

Septerna-Aktie explodiert nach Milliarden-Deal mit Novo Nordisk

Die Aktie des US-amerikanischen Biotechunternehmens Septerna (NASDAQ: SEPN) verzeichnete am Mittwoch,...

  • ‹
  • 1
  • ›
Septerna Nachrichtenticker öffnen
MT Newswires 10.08.2026 22:27 Uhr

Septerna Q2-Verlust verringert sich, Umsatz steigt

04:26 PM EDT, 10.08.2026 (MT Newswires) -- Septerna (SEPN) meldete am späten Montag einen Verlust im Q2 von 0,29 USD je verwässerter Aktie, was eine V

MT Newswires 10.08.2026 22:17 Uhr

-- Earnings Flash (SEPN) Septerna verzeichnet Q2 Verlust je Aktie von 0,29 USD, vs. FactSet-Schätzung von 0,43 USD Verlust

04:16 PM EDT, 08/10/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 10.08.2026 22:03 Uhr

-- Earnings Flash (SEPN) Septerna, Inc. meldet Q2-Umsatz von 26,7 Mio. $, gegenüber FactSet-Schätzung von 19,2 Mio. $

04:02 PM EDT, 08/10/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 01.07.2026 14:47 Uhr

Truist Securities passt Kursziel für Septerna von 35 $ auf 43 $ an, behält Kaufempfehlung bei

08:46 AM EDT, 07/01/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 11.06.2026 12:41 Uhr

Guggenheim nimmt die Coverage für Septerna mit 'Kaufen'-Rating und einem Kursziel von 52 $ auf

06:40 AM EDT, 06/11/2026 (MT Newswires) -- Septerna (SEPN) hat ein durchschnittliches 'Kaufen'-Rating und ein mittleres Kursziel von 45 $, laut Analys